🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Fun collaboration with the Sadelain Lab Memorial Sloan Kettering Cancer Center, led by Michelle Saetersmoen, Ivan Kotchetkov and Lamberto Torralba-Raga. Targeting HLA-E Positive Cancers with a Novel NKG2A/C Switch Receptor Precision Immunotherapy Alliance UiO - Det medisinske fakultet Oslounivsykehus biorxiv.org/content/10.110…

Proud of Jess Root and Poonam Desai in the lab for coleading this work. Looking at niche (BM vs PB) and temporal functional states of T cells in AML following IO. Rare cohort. Naval Daver, M.D. Patrick Reville, MD, MPH aacrjournals.org/cancerrescommu…

Excited to share our latest work now published Nature Communications characterizing the role of IFNg signaling in AML and its implications on AML differentiation, therapy resistance, and immune microenvironment. Bofei Wang Hussein Abbas nature.com/articles/s4146…

Nice work from Patrick Reville, MD, MPH and colleagues. HLA-E expression on AML blasts higher in cells with monocytic differentiation, del7/7q. Driven by IFN-gamma enabling NK evasion via interaction with NKG2A. See also doi.org/10.1016/j.immu… from Olli Dufva @DrSGandalf

New #JITC article: Paired single-B-cell transcriptomics and receptor sequencing reveal activation states and clonal signatures that characterize B cells in acute myeloid leukemia bit.ly/4bUZxIu Gopi Mohan MD, PhD Patrick Reville, MD, MPH Hussein Abbas

Another story from the lab fresh in the press! Studying B cells and their repertoires; the unsung players in AML. Kudos to the team work and collaborative efforts. Patrick Reville, MD, MPH DP Hao Nance and Gopi Mohan MD, PhD. MD Anderson Cancer Center

Very excited to share our new paper on how mutations in SWI/SNF chromatin remodeling complexes alter chromatin dynamics and immune cell-fate to drive lymphoma, online now in Cancer Cell. authors.elsevier.com/c/1ijJ05TA51hO… More details in the thread below.👇 🧵 1/n

& don't miss the incredible accompanying story by Michael Green, PhD on SMARCA4 side of the story. authors.elsevier.com/sd/article/S15…

How do BAF (SWI/SNF) mutations drive lymphoma? Back-to-back papers from our group MD Anderson Cancer Center and Melnick Lab lab on SMARCA4 and ARID1A mutations online in Cancer Cell today. A brief summary... sciencedirect.com/science/articl…

Here’s a closer look at recent #JITC article “Paired single-B-cell transcriptomics & receptor sequencing reveal activation states & clonal signatures that characterize B cell immunity in AML” by Hussein Abbas @PatrickReville Gopi Mohan MD, PhD Shengnan Guo DP Hao from

Consensus Recommendations from the 2024 Lymphoma Research Foundation Workshop on Treatment Selection and Sequencing in CLL or SLL ashpublications.org/bloodadvances/… It was awesome to collaborate with great colleagues and friends on this! Thanks Lymphoma Research Foundation for the support. Deborah Stephens

Atezo+VO 1L CLL Patrick Reville, MD, MPH #ASH24: - 37 pts, no TP53/del17p, mFU 40 mos - 4-yr PFS 89%, OS 94% - 97% BMBx uMRD4, 3 PD events but no subsequent tx req'd - 3 pts d/c'd d/t irAEs (colitis, hepatitis) Transcriptomic data attached. Fascinating! #leusm #lymsm

Our Dr. Patrick Reville presented results at #ASH24 of a trial of Atezolizumab combined with Venetoclax and Obinutuzumab as a first-line treatment for patients with chronic lymphocytic leukemia (CLL) that showed a four-year overall survival rate of 94%. Patrick Reville, MD, MPH #EndCancer

Featured on the new journal cover: Single-Cell CD4 and CD8 T-Cell Secretome Profiling Reveals Temporal and Niche Differences in Acute Myeloid Leukemia Following Immune Checkpoint Blockade Therapy brnw.ch/21wQbfm Hussein Abbas Naval Daver, M.D. Patrick Reville, MD, MPH

➡️ Excited to share the phase 1b/2 clin trial of Aza-Ven-Magro in ND high-risk & R/R AML from MD Anderson Cancer Center led by Naval Daver, M.D., just out in Clinical Cancer Research ✅ Interesting correlative analysis by Hussein Abbas interrogating mech of Magro resistance in TP53-mut AML ✅Despite

MD Anderson researchers recently identified an eight-protein blood signature to help predict outcomes for patients with acute myeloid leukemia. One protein stood out as a key predictor of survival and early treatment risk. Learn more: brnw.ch/21wRT0h #EndCancer

Our new publication is out today in the OnlineFirst section of Blood Cancer Discovery! We explored correlations between monocytic AML, genetics, and survival by leveraging a large international clinical cohort of patients with AML treated with HMA+VEN. aacrjournals.org/bloodcancerdis…

Multimodal spatial proteomic profiling in acute myeloid leukemia nature.com/articles/s4169…

New paper, we used spectral flow cytometry panels to characterize AML and T cells. Hussein Abbas Comprehensive Profiling of AML and T Cell States Across Disease Stages in Acute Myeloid Leukemia Using Spectral Flow Cytometry ashpublications.org/bloodict/artic…